Although more women than men have pulmonary arterial hypertension, several PAH medications are teratogenic, according to a ...

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Reduced diffusing capacity of the lungs for carbon monoxide (DLco) reflects microvasculopathy in chronic thromboembolic ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension ...

The biotech posted preliminary sales results for Yutrepia. This is its latest commercialized product, approved by the FDA in ...

A 40-year-old woman who was once accustomed to frequent travel suddenly found herself struggling to breathe after just a few ...

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year ...

A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.

Estimated YUTREPIA net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in Jun ...

With a $125 million series B financing round, Diagonal Therapeutics has made a vertical move to advance its first-in-class ...

Merck is in talks ​to buy cancer drug developer Revolution Medicines in a USD 28 billion ⁠to USD 32 billion deal, the ...